Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX

doi:10.3748/wjg.v16.i17.2163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 17

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3053)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

336

HTML

2439

Figures (1-2)

135

Tables (1-3)

143

Sum=3053

May 7, 2010 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 7, 2010; 16(17): 2163-2169
Published online May 7, 2010. doi: 10.3748/wjg.v16.i17.2163

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier estimates of overall survival by vascular endothelial growth factor receptor-3 (VEGFR-3) levels (n = 81, low VEGFR-3: 52; high VEGFR-3: 29).

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier estimates of overall survival according to VEGFR-3 levels in patients. A: Patients with high carcinoembryonic antigen (CEA) levels (n = 24, high CEA and low VEGFR-3: 13, high CEA and high VEGFR-3: 11); B: Patients with low CEA levels (n = 57; low CEA and low VEGFR-3: 39; low CEA and high VEGFR-3: 18).

Citation: Ni XF, Wu CP, Jiang JT. Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX. World J Gastroenterol 2010; 16(17): 2163-2169
URL: https://www.wjgnet.com/1007-9327/full/v16/i17/2163.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i17.2163